Objectives: To investigate effects on surveillance results of hospital antibiotic use when WHO defined daily doses (WHO DDDs) are adjusted to doses recommended for hospitalized patients [hospital-adjusted defined daily doses (haDDDs)].
Introduction
Since its original development almost 35 years ago, the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) system has evolved into an international standard for drug metrics. The WHO defined daily doses (WHO DDDs) are technical units of measurement that aim to reflect the average maintenance dose per day for a drug used for its main indication in adults. 1 For hospital patients, however, the WHO DDDs are not always consistent with the recommended antibiotic doses or the doses that are actually prescribed. In general, the WHO DDDs for several antibiotics are set too low, which may lead to false surveillance results of antibiotic utilization in hospitals. 2, 3 A few researchers have addressed this problem and have described errors that might arise because of these discrepancies. 4 -7 However, a thorough analysis applied on the hospital patient population of an entire country has to our knowledge not been undertaken.
We aimed to investigate the implications for antibiotic surveillance results in hospitals by applying hospital-adjusted defined daily doses (haDDDs), compared with the use of WHO DDDs.
Methods

Study hospitals [Health Enterprises (HEs)]
Surveillance data from 2006 to 2011 (6 years) were examined for five university HEs, 14 large general HEs and three private HEs in Norway. Each HE consists of one to seven geographically separated hospitals and covers a complete and comparable range of specialties, with the exception of units for transplantation, heart surgery, neurosurgery, burns and multitrauma, which are only located at the university institutions. The three private institutions contain mainly general internal medicine, surgery and intensive care units. We excluded four specialized private institutions for elective orthopaedics, rheumatology, heart surgery and rehabilitation since they electively treat very selected patients groups, as well as all # The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2013; 68: 2940 -2947 doi:10.1093/jac/dkt268 Advance Access publication 9 July 2013 psychiatric and substance-abuse wards and institutions because their antibiotic consumption is negligible and their affiliation to the HEs is very variable.
The 22 HEs provide somatic healthcare to the Norwegian population of 5 million inhabitants with a total number (annual average for 2006 -11) of 12272 hospital beds (mean number per HE, 558 beds; range, 152-2261). In 2011, 850564 hospitalizations were recorded, with patients occupying 11730 hospital beds for a total of 3 663482 bed days (BDs). The five university hospitals accounted for 39% of patient stays, 40% of hospital beds and 41% of BDs; respective numbers for the large general hospitals were 57%, 56% and 55%, while the private hospitals accounted for 4% for all parameters.
Antibiotic use
Data were obtained from a national database maintained by the national Hospital Pharmacy Enterprise, to which all hospital pharmacies report their sales data on a daily basis. We registered all substances belonging to ATC/DDD group J01 and systemic antibacterial agents (except J01XX05, methenamine, a urine antiseptic), as well as A07AA09 (oral vancomycin), J04AB02 (rifampicin) and P01AB01 (metronidazole, oral and rectal formulations-the latter sparsely used) and used the term 'total antibiotics' for these substances. Subgroup analyses were performed for 'broad-spectrum antibiotics' (defined as second-and third-generation cephalosporins, fluoroquinolones, carbapenems and penicillins with enzyme inhibitors) and 'all penicillins' (defined as all penicillins not classified as 'broad-spectrum', i.e. penicillinase-sensitive, penicillinase-resistant and extended-spectrum penicillins). We classified all the remaining antibiotics as 'other antibiotics'. The WHO ATC/DDD version 2011 was used. 8 
haDDDs
We examined the hospital antibiotic guidelines published by the four Regional HEs for 2006-09 and a national antibiotic guideline from 2001 9 to determine the haDDDs based on recommended doses. Because there was more than one main indication for several antibiotics, in particular for the penicillins and cephalosporins, we distinguished the doses recommended for moderately severe infections [e.g. community-acquired pneumonia (CAP)] from those recommended for severe infections (e.g. sepsis and meningitis). We then estimated the midvalues between the recommended doses for these indications and defined them as the haDDDs. The relative occurrences of moderate and severe infections were taken into account in the calculation of these estimates. To help estimate these ratios, discharge diagnoses from 2006 to 2011 of patients from HEs in south-east Norway were acquired from the Norwegian Patient Registry (NPR), a department of the Health Directorate. For example, we estimated the ratio of CAP episodes to sepsis/meningitis episodes to be 10: 1 and adjusted the haDDD midvalue for benzylpenicillin accordingly. With regard to the aminoglycosides gentamicin and tobramycin, which are used extensively in Norway, we did not adjust the WHO-assigned DDDs of 240 mg. Although the recommended initial doses of 5 mg/kg per day would imply a higher haDDD, the maintenance doses are usually lower because of a large hospital population of elderly patients, among whom renal impairment is prevalent. 10 Such dose reductions are recommended in the local guidelines. Furthermore, the use of substantially lower prescribed doses for aminoglycoside than recommended in the guidelines (and even lower than the WHO DDDs) has been reported by other investigators. 4, 7 Administrative and clinical data
The length of hospital stay was measured as occupied BDs, defined as the date of discharge minus the date of admission. The number of BDs and the numberof hospital discharges were acquired from an Internet database published by the NPR. 11 The NPR is responsible for quality control and publication of the administrative data that are collected annually from all health institutions. This simplifies the acquisition of reliable national surveillance data, which do not have to be requested from each HE. The NPR database does not allow differentiation of administrative levels lower than whole HEs. This means that details about hospital units within each HE (i.e. the different departments and wards) are not readily available. However, we were able to specify and select all somatic specialities as an entity, thus assuring that the administrative dataset matched our data on antibiotic use.
Data processing and statistical analysis
The administrative and pharmacy data were imported into a Microsoft Excel (2010) A P value ,0.05 was considered significant; all tests were two-tailed. We used the method for ranking drug utilization [drug utilization 90% (DU90%)] first described by Bergman et al. 12 In this ranking we chose not to analyse the antibiotics according to the route of administration, but rather on the basis of substances that have a similar spectrum of antimicrobial activity and exert an essentially equal effect with regard to prophylaxis and treatment. Examples of such groupings are ciprofloxacin/ofloxacin, cloxacillin/dicloxacillin, ampicillin/pivampicillin and narrow-spectrum penicillins. This way of categorizing antibiotics provided a clinically relevant assessment of ranking differences, whether the ranking was based on WHO DDD or haDDD metrics.
Ethical approval
None required.
Results
WHO DDDs versus haDDDs
The dosing recommendations in all antibiotic guidelines were largely similar. A total of 24 antibiotics were identified for which the WHO-assigned DDD differed significantly, i.e. at least +10%, from the dose normally used in hospitalized patients. This resulted in 27 adjustments of the parenteral and/or oral dose assignments (Table 1) . Altogether, 76 antibiotic formulations were used in the 22 hospitals during the study period. Of these, 18 substances are neither approved nor marketed in Norway, e.g. amoxicillin/clavulanate, cefixime, ceftibuten, flucloxacillin, levofloxacin, moxifloxacin and ticarcillin/clavulanate. Their use contributed only 0.14% of the total amount of WHO DDDs. Although the WHO DDDs for several of these substances most probably deviate from doses used in hospitals, as shown by others, 4, 7 there were sparse recommendations for their use in Norwegian guidelines. Consequently, no reliable haDDDs could be defined for the antibiotics not authorized.
In general, the haDDDs (in grams) were considerably higher than the WHO DDDs and the extents of the differences were similar for the oral and parenteral drugs (Table 1) .
Implications for surveillance results
The mean accumulated total antibiotic use calculated per HE was 67.1 WHO DDDs/100 BDs and 49.3 haDDDs/100 BDs, a difference DDD adjustments for surveillance of hospital antibiotic use of 226.4% (Table 2 ). For broad-spectrum antibiotics, the respective figures were 17.3 WHO DDDs/100 BDs and 15.5 haDDDs/100 BDs (mean difference, 210.4%). For all penicillins, the respective figures were 31.1 WHO DDDs/100 BDs and 13.4 haDDDs/100 BDs (mean difference, 256.8%).
For orally administered drugs, the adjustments for total antibiotic use resulted in the following: 20.9 WHO DDDs/100 BDs and 16.8 haDDDs/100 BDs (219.6%). The corresponding figures for parenteral drugs were 46.2 WHO DDDs/100 BDs and 32.5 haDDDs/100 BDs (229.7%).
The changes resulting from the conversion to haDDDs varied between the HEs by a factor of two for the total antibiotics [range, 239.7% to 219.6%; standard deviation (SD), 3.3; P,0.0001]. For the broad-spectrum antibiotics, the variation was 5-fold (range, 216.7% to 23.3%; SD, 2.9; P,0.0001), whereas there was little variation for the penicillins (range, 260.0% to 252.7%; SD, 1.8; P,0.0001). The average haDDDs/100 BDs for other antibiotics was 8.7% higher than the WHO DDDs/100 BDs, largely caused by a downward DDD adjustment for clindamycin and metronidazole. Figure 1 shows the WHO DDDs and haDDDs according to the type of HE and the antibiotic group. With regard to total antibiotic use, the application of haDDDs implied 24.2% (60.8 WHO DDDs to 46.1 haDDDs) lower DDDs per 100 BDs for university HEs, 26.6% (67.3 WHO DDDs to 49.4 haDDDs) lower for large general HEs and 29.2% (76.0 WHO DDDs to 53.8 haDDDs) lower for private HEs (all differences significant, P,0.001). In all three types of institution, the differences between WHO DDDs and haDDDs were driven by the dose conversions for penicillins; for broad-spectrum antibiotics or other antibiotics, no significant differences were found.
The use of all penicillins constituted 46.0% of total antibiotic use (inter-HE range, 34.2%-66.7%; SD, 5.2; P¼ 0.005) when measured in WHO DDDs and was lowered to 27.1% (inter-HE range, 17.7% -44.6%; SD, 4.3; P,0.001) when measured in haDDDs. In contrast, the proportion represented by the broad-spectrum antibiotics increased from 25.9% with WHO DDDs (inter-HE range, 10.4%-34.0%; SD, 3.6%; P ¼0.007) to 31.4% with haDDDs (inter-HE range, 14.9% -38.4%; SD, 3.6%; P ¼0.001).
DU90% ranking
Twenty-four antibiotics were registered within the 90th percentile and every HE ranked ≥13 antibiotics within the DU90%. The individual rankings for each antibiotic as a consequence of applying WHO DDD or haDDD metrics are summarized in Table 3 . The penicillinase-sensitive penicillins ranked number one in all 22 HEs when measured with WHO DDDs, but in only 8 HEs when haDDDs were used. The antibiotics taking the remaining number one positions by use of haDDD metrics were metronidazole, cefuroxime, Haug and Reikvam cefotaxime and cefalotin/cefalexin. Overall, dicloxacillin/cloxacillin and the penicillins with extended spectrum were ranked lower, whereas ciprofloxacin and cefalotin were ranked higher with the haDDD metrics than with the WHO DDD metrics. Higher ranking also applied for the tetracyclines.
Temporal trends from 2006 to 2011
From 2006 to 2011, there was an increase in the total antibiotic use from 62.7 to 73.0 WHO DDDs/100 BDs (16.5%; P,0.005) and from 45.7 to 53.5 haDDDs/100 BDs (17.1%; P,0.001). However, when measured per 100 discharges, the total antibiotic use did not change significantly; the percentage changes were 20.02% and 0.8% when the WHO DDDs and haDDDs were applied, respectively. There was an increase in the use of broad-spectrum antibiotics in the period 2006 -11, from 15.4 to 18.7 WHO DDDs/100 BDs (21.3%; P,0.001) and from 13.9 to 16.6 haDDDs/100 BDs (19.7%; P, 0.002). The corresponding percentages per 100 patient discharges were 4.6% and 23.3%, respectively [both non- 
Discussion
This study shows that the adjustment of WHO DDDs to doses appropriate for hospital patients led to significant changes in the measurements of total antibiotic use. In general, the use of WHO DDDs implies an overestimation of the use of antibiotics in hospitals. In particular, the WHO DDDs for penicillins are set too low, meaning that the actual use is only half of the amount reported on the basis of WHO dose definitions. In contrast, for broad-spectrum antibiotics-which are mainly administered parenterally-only modest adjustments were needed, resulting in slightly lower figures for hospital use when measurements were made with haDDDs rather than with WHO DDDs.
For surveillance purposes, the broad-spectrum antibiotics are particularly important to target, since an increased use may be accompanied by the development of antibiotic resistance. The too low setting of WHO DDDs for penicillins implies that broadspectrum antibiotics constitute a higher proportion of the total 
JAC
antibiotic use than what is generally reported. Therefore, the real magnitude of broad-spectrum antibiotic use will be masked. Discrepancies between the doses recommended for hospital patients and the DDDs assigned by WHO have been reported for non-university hospitals in southwestern Germany. 5 In that study, the hospital-adjusted doses for oral ciprofloxacin, benzylpenicillin and amoxicillin/clavulanate-the latter drug is not registered and is used only sparsely in Norway-were set somewhat higher than the estimates used by us. However, the overall results were consistent with our findings. In a study from a single university hospital in France, hospital dose adjustment resulted in 40% lower estimates of antibiotic use compared with the measurements based on the WHO DDDs. 7 This is a larger difference than that found in the present study (26%) and is probably attributable to the specific profile of antibiotic use in that particular hospital, where amoxicillin, amoxicillin/clavulanate and ciprofloxacin accounted for more than half of the total antibiotic use.
Importantly, the impact of using haDDDs instead of WHO DDDs varied between the different HEs and the largest interhospital variations were observed for the broad-spectrum antibiotics. Both the percentage DDD changes related to the WHO DDD-to-haDDD conversion and the proportion that broad-spectrum antibiotics constituted of the total antibiotic utilization varied markedly between HEs. Our findings indicate that within a single country, haDDDs are best suited for interinstitutional comparisons of antibiotic utilization.
It was recently suggested by the European Surveillance of Antimicrobial Consumption (ESAC) collaboration for the analysis of antibiotic use in European hospitals that the drug utilization ranking of antibiotic use be cut at the 75% percentile (DU75%). 13 However, because the number of approved and used antimicrobials in Norwegian hospitals is rather small, we chose to rank them within the 90% percentile in this study. By applying the DU90% methodology, we found that 19 drugs constituted the most frequently used antibiotics-based on counting by the active substances and not by the route of administration. In the ESAC study, which included 17 European hospitals, 51 drugs (route of administration not considered) were represented at least once within the DU75%. 13 The fact that significantly fewer antibiotic substances are marketed in Norway than in other European countries is probably a major explanatory factor for the still moderate antibiotic resistance problem in Norwegian hospitals. 14 The use of haDDDs changed the ranking of antibiotics within the DU90% such that antibiotics other than the penicillins were ranked high, notably metronidazole, tetracyclines, fluoroquinolones and cephalosporins. Metronidazole and doxycycline (which constituted 94.5% of the tetracyclines) is standard antibiotic prophylaxis for abdominal surgery in Norway. Metronidazole is also the most frequently used drug for anaerobic gastrointestinal and genitourinary infections. Fluoroquinolones (96.5% ciprofloxacin) and cephalosporins are highly interesting in terms of surveillance, the purpose of which is to focus on the untoward use of antibiotics and thus reduce the risk of antibiotic resistance. 15 For example, cefalotin is barely used therapeutically, but it is the most frequently used drug for non-abdominal surgical prophylaxis in our country and its real utilization may be masked. Penicillins topped the ranking when surveillance was performed with the WHO DDDs, but this does not reflect the real-world situation. The use of haDDDs gave a more diverse ranking of the antibiotics and appears to be a more suitable tool for detecting subtle changes.
As expected, the extent of the change in antibiotic use over time was largely the same regardless of whether the WHO DDDs or haDDDs were used as the numerator. Furthermore, our study corroborates the importance of an appropriately applied denominator in the evaluation of temporal trends. The use of the number of 
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The figures show the number of HEs within each rank. The matter was recently investigated in a large ESAC study using longitudinal data from 18 European hospitals. 17 Their recommendation was that to be reliable, any trends in antibiotic use and comparisons between hospitals need to be measured with both indices of clinical activity. Another conclusion from that study, which is in line with our own surveillance strategy, was that centralized and standardized data acquisition is the most reliable method for comparison of antibiotic use between hospitals.
Previously, we have shown an increase in antibiotic use in hospitals based on WHO DDDs/100 BDs for a large region in Norway in the period 2002-07. 18 The increase in total antibiotic use from 2006 to 2011, observed in the present study, is of the same magnitude as that in the preceding period (17%), but occurred at a somewhat lower WHO DDD level. This may be explained by the enrolment of all Norwegian hospitals in the present study, including paediatric departments, which meant the inclusion of wards with low antibiotic use. However, for the broad-spectrum antibiotics, the increase in use that occurred in this study period was less than half the increase we observed in the previous period (21% versus 48%). This might indicate that the increase in broad-spectrum antibiotic use actually levelled off from 2006 to 2011, which is indeed a positive development.
One aim of this study was to find methods that are suitable for routine national surveillance, where gross comparisons are more important than detailed analyses at the level of individual hospitals. Therefore, we refrained from the exhaustive task-perhaps even a dubious task with regard to data quality-of obtaining more detailed administrative data from each individual HE. We think that subanalyses of university, large general and private HEs should suffice in the context of national surveillance. This approach allowed us to extract the relevant information, because the medical services are relatively similar within each of these categories of institutions.
The few other studies that have addressed DDD adjustments for antibiotics have been confined to hospitals of a specific category 5 or even to single hospitals 4, 6, 7 and have had short observation periods. Two strengths of our study are the inclusion of all Norwegian HEs and the fact that they were studied for a long period of time. These features lend support to our conclusion that it is advantageous to apply hospital dose adjustments in national surveillance. Neither extrapolations nor reservations with regard to hospital type or geographic area are required. A limitation of the study is that the antibiotic dose adjustments were based on the recommended doses from guidelines for antibiotic use and not based on the prescribed doses, documented, e.g. from patient chart reviews. In Norway, a point prevalence system for antibiotic use in hospitals has been developed, as an extension of the established national system for hospital infection surveillance. 19 However, so far the database does not contain enough information to allow robust calculations of prescribed daily doses.
In conclusion, we found that the use of the WHO DDDs significantly skewed the surveillance results for Norwegian hospitals and that more reliable data could be obtained by applying DDDs based on the doses recommended for use in hospital patients. Furthermore, the use of haDDDs improved the likelihood of detecting differences between institutions. We propose that both haDDDs and WHO DDDs-for international comparisons-should be part of a national antibiotic surveillance system.
